- Home
- SID vs IOVA Comparison
SID vs IOVA Comparison
Compare SID & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SID
- IOVA
- Stock Information
- Founded
- SID 1941
- IOVA 2007
- Country
- SID Brazil
- IOVA United States
- Employees
- SID N/A
- IOVA N/A
- Industry
- SID Steel/Iron Ore
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SID Industrials
- IOVA Health Care
- Exchange
- SID Nasdaq
- IOVA Nasdaq
- Market Cap
- SID 2.7B
- IOVA 3.0B
- IPO Year
- SID 1997
- IOVA N/A
- Fundamental
- Price
- SID $1.99
- IOVA $8.55
- Analyst Decision
- SID Sell
- IOVA Strong Buy
- Analyst Count
- SID 2
- IOVA 9
- Target Price
- SID $2.95
- IOVA $23.33
- AVG Volume (30 Days)
- SID 2.4M
- IOVA 8.8M
- Earning Date
- SID 11-12-2024
- IOVA 11-07-2024
- Dividend Yield
- SID 14.72%
- IOVA N/A
- EPS Growth
- SID N/A
- IOVA N/A
- EPS
- SID N/A
- IOVA N/A
- Revenue
- SID $8,019,254,042.00
- IOVA $90,858,000.00
- Revenue This Year
- SID N/A
- IOVA $13,827.67
- Revenue Next Year
- SID $1.48
- IOVA $183.70
- P/E Ratio
- SID N/A
- IOVA N/A
- Revenue Growth
- SID N/A
- IOVA 12751.20
- 52 Week Low
- SID $1.82
- IOVA $5.41
- 52 Week High
- SID $4.03
- IOVA $18.33
- Technical
- Relative Strength Index (RSI)
- SID 45.84
- IOVA 38.84
- Support Level
- SID $1.94
- IOVA $7.98
- Resistance Level
- SID $2.21
- IOVA $10.86
- Average True Range (ATR)
- SID 0.07
- IOVA 0.64
- MACD
- SID 0.00
- IOVA -0.26
- Stochastic Oscillator
- SID 42.31
- IOVA 12.58
About SID Companhia Siderurgica Nacional S.A.
Companhia Siderurgica Nacional is an integrated steel producer. The company operate throughout the entire steel production chain, from the mining of iron ore to the production and sale of a diversified range of steel products. It operates in five segments namely, Steel, Mining, Logistics, Energy, and Cement. It generates maximum revenue from the steel segment. Geographically, it derives a majority of revenue from Asia.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.